JP2021521856A5 - - Google Patents
Info
- Publication number
- JP2021521856A5 JP2021521856A5 JP2020560400A JP2020560400A JP2021521856A5 JP 2021521856 A5 JP2021521856 A5 JP 2021521856A5 JP 2020560400 A JP2020560400 A JP 2020560400A JP 2020560400 A JP2020560400 A JP 2020560400A JP 2021521856 A5 JP2021521856 A5 JP 2021521856A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- foxp3
- cells
- promoter
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024182581A JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663545P | 2018-04-27 | 2018-04-27 | |
| US62/663,545 | 2018-04-27 | ||
| PCT/US2019/029082 WO2019210042A1 (en) | 2018-04-27 | 2019-04-25 | Expression of foxp3 in edited cd34+ cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024182581A Division JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521856A JP2021521856A (ja) | 2021-08-30 |
| JP2021521856A5 true JP2021521856A5 (https=) | 2022-11-25 |
| JP7575950B2 JP7575950B2 (ja) | 2024-10-31 |
Family
ID=68294731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Active JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2024182581A Active JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024182581A Active JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11713459B2 (https=) |
| EP (1) | EP3784690A4 (https=) |
| JP (2) | JP7575950B2 (https=) |
| CN (1) | CN112218882A (https=) |
| AU (2) | AU2019261438B2 (https=) |
| CA (1) | CA3091688A1 (https=) |
| IL (1) | IL277039A (https=) |
| SG (1) | SG11202007878UA (https=) |
| WO (1) | WO2019210042A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042179A1 (en) | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| CA3091491A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| AU2019261438B2 (en) * | 2018-04-27 | 2024-08-22 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of FOXP3 in edited CD34+ cells |
| KR20210116531A (ko) * | 2019-01-18 | 2021-09-27 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 영양 장애형 표피 수포증 치료약 |
| JP2022533713A (ja) | 2019-05-21 | 2022-07-25 | サンガモ セラピューティクス， インコーポレイテッド | 調節性ｔ細胞における制御された導入遺伝子発現 |
| WO2020264039A1 (en) * | 2019-06-27 | 2020-12-30 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Artificial antigen-specific immunoregulatory t (airt) cells |
| JP2023501388A (ja) | 2019-11-08 | 2023-01-18 | サンガモ セラピューティクス， インコーポレイテッド | 操作された制御性ｔ細胞の生成 |
| WO2021144692A1 (en) * | 2020-01-14 | 2021-07-22 | Crispr Therapeutics Ag | Methods for increased efficiency of homology-directed repair |
| EP4103591A4 (en) | 2020-02-13 | 2024-09-04 | The Board of Trustees of the Leland Stanford Junior University | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients |
| AU2021368557A1 (en) * | 2020-10-27 | 2023-06-08 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using next generation engineered t cell therapy |
| CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100996016B1 (ko) | 2000-09-20 | 2010-11-22 | 밀리포어 코포레이션 | 폴리뉴클레오티드 |
| EP1967525B1 (en) | 2001-05-08 | 2012-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
| GB0614536D0 (en) | 2006-07-21 | 2006-08-30 | Metcalfe Susan M | Methods of controlling cellular response to LIF |
| EP2064350B1 (en) * | 2006-11-27 | 2013-01-02 | Ludwig Institute for Cancer Research Ltd. | Expression of foxp3 by cancer cells |
| EP2126054B1 (en) | 2007-01-31 | 2016-07-06 | Yeda Research And Development Company Limited | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| WO2008101272A1 (en) * | 2007-02-21 | 2008-08-28 | Women's And Children's Health Research Institute Inc | Method for obtaining treg-cells |
| US8158596B2 (en) | 2007-05-11 | 2012-04-17 | The Regents Of The University Of Michigan | Materials and methods for FOXP3 tumor suppression |
| US8846308B2 (en) | 2007-06-08 | 2014-09-30 | The Trustees Of The University Of Pennsylvania | Method for identifying immune response modulators |
| JP2011503232A (ja) | 2007-11-20 | 2011-01-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫応答の調節 |
| TW200942246A (en) | 2008-03-03 | 2009-10-16 | Fabio Grassi | Method of modulating T cell-dependent immune responses |
| WO2012018930A1 (en) | 2010-08-03 | 2012-02-09 | University Of Miami | Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy |
| WO2014180943A1 (en) | 2013-05-08 | 2014-11-13 | Vib Vzw | Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders |
| AU2014266833B2 (en) | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| WO2015121454A1 (en) | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| AU2015233347A1 (en) | 2014-03-21 | 2016-09-08 | Cellectis | Engineering mammalian genome using DNA-guided Argonaute interference systems (DAIS) |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| CN107250373A (zh) | 2015-01-12 | 2017-10-13 | 麻省理工学院 | 通过微流体递送实现的基因编辑 |
| WO2016123578A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Protein delivery in primary hematopoietic cells |
| CN107921148A (zh) * | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| EP3497221A4 (en) | 2016-08-10 | 2020-02-05 | Duke University | COMPOSITIONS, SYSTEMS AND METHODS FOR PROGRAMMING IMMUNE CELL FUNCTION BY TARGETED GENE REGULATION |
| MA45996A (fr) * | 2016-08-16 | 2021-06-02 | Bluebird Bio Inc | Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| AU2017347854B2 (en) | 2016-10-27 | 2022-12-08 | Intima Bioscience, Inc. | Viral methods of T cell therapy |
| CA3042179A1 (en) | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| CN110191955B (zh) | 2016-12-13 | 2024-05-31 | 西雅图儿童医院（Dba西雅图儿童研究所） | 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法 |
| CN109790518A (zh) * | 2017-05-08 | 2019-05-21 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| WO2019040655A1 (en) | 2017-08-22 | 2019-02-28 | The Regents Of The University Of California | LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES |
| CA3091491A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| AU2019261438B2 (en) * | 2018-04-27 | 2024-08-22 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of FOXP3 in edited CD34+ cells |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
-
2019
- 2019-04-25 AU AU2019261438A patent/AU2019261438B2/en active Active
- 2019-04-25 CN CN201980028370.7A patent/CN112218882A/zh active Pending
- 2019-04-25 EP EP19793428.4A patent/EP3784690A4/en active Pending
- 2019-04-25 SG SG11202007878UA patent/SG11202007878UA/en unknown
- 2019-04-25 CA CA3091688A patent/CA3091688A1/en active Pending
- 2019-04-25 JP JP2020560400A patent/JP7575950B2/ja active Active
- 2019-04-25 WO PCT/US2019/029082 patent/WO2019210042A1/en not_active Ceased
- 2019-04-25 US US16/981,223 patent/US11713459B2/en active Active
-
2020
- 2020-08-31 IL IL277039A patent/IL277039A/en unknown
-
2023
- 2023-06-16 US US18/336,276 patent/US20240117352A1/en active Pending
-
2024
- 2024-10-18 JP JP2024182581A patent/JP7844582B2/ja active Active
- 2024-11-22 AU AU2024266824A patent/AU2024266824A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521856A5 (https=) | ||
| JP2021521849A5 (https=) | ||
| US20240033300A1 (en) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene | |
| AU2021277627B2 (en) | Anti-CD70-chimeric antigen receptors | |
| US20190322983A1 (en) | Engineered treg cells | |
| JP2025013884A5 (https=) | ||
| JP2025013879A5 (https=) | ||
| JP2020529834A5 (https=) | ||
| JP2019521659A5 (https=) | ||
| JP2015078191A5 (https=) | ||
| JP2018524267A (ja) | 持続療法用のナノ粒子組成物 | |
| Bucciol et al. | Recent advances in primary immunodeficiency: from molecular diagnosis to treatment | |
| US20220378025A1 (en) | Genetically modified non-human animal with human or chimeric genes | |
| JP2024505075A5 (https=) | ||
| JP2024514355A5 (https=) | ||
| Lantow et al. | The granulocyte colony stimulating factor pathway regulates autoantibody production in a murine induced model of systemic lupus erythematosus | |
| US20250195572A1 (en) | Methods and compositions comprising fusion proteins for improved immunotherapies | |
| JP2025515095A (ja) | Ｈｌａ－ｅおよびｈｌａ－ｇ導入遺伝子を用いて操作された細胞 | |
| JP2024515347A5 (https=) | ||
| CN118451181A (zh) | 工程化用于基于细胞的疗法的细胞以及相关组合物和方法 | |
| Cicalese et al. | Gene Therapy for Primary Immunodeficiencies |